Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy
- 27 March 2008
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 19 (5) , 1022-1024
- https://doi.org/10.1093/annonc/mdn121
Abstract
With respect to treatment monitoring, conventional modalities such as physical examination, ultrasonography, and mammography are frequently used, but vary in reliability for measuring tumor's therapeutic response [1, 2]. Magnetic resonance imaging (MRI) is increasingly being used to evaluate locally advanced breast cancer undergoing neo-adjuvant chemotherapy. However, changes in lesion size or dynamic contrast enhanced MRI are not detected until several weeks following chemotherapy [3].Keywords
This publication has 7 references indexed in Scilit:
- Quantification of Choline-containing Compounds in Malignant Breast Tumors by 1H MR Spectroscopy Using Water as an Internal Reference at 1.5 TMagnetic Resonance Materials in Physics, Biology and Medicine, 2006
- Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapyEuropean Radiology, 2002
- Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancerBritish Journal of Cancer, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Characterization of neoplastic and normal human breast tissues with in vivo1H MR spectroscopyJournal of Magnetic Resonance Imaging, 1999
- Imaging procedures for assessment of the response of mammary carcinoma to preoperative chemotherapyDer Radiologe, 1997
- Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.1997